Susan M Domchek1, Carol Aghajanian2, Ronnie Shapira-Frommer3, Rita K Schmutzler4, M William Audeh5, Michael Friedlander6, Judith Balmaña7, Gillian Mitchell8, Georgeta Fried9, Salomon M Stemmer10, Ayala Hubert11, Ora Rosengarten12, Niklas Loman13, Jane D Robertson14, Helen Mann14, Bella Kaufman3. 1. Basser Research Center and Abramson Cancer Center, Philadelphia, PA, USA. Electronic address: susan.domchek@uphs.upenn.edu. 2. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. 3. Sheba Medical Center, Tel Hashomer, Israel. 4. Center for Familial Breast and Ovarian Cancer and Center of Integrated Oncology, Cologne, Germany. 5. Samuel Oschin Cancer Institute, Los Angeles, CA, USA. 6. Prince of Wales Clinical School, University of New South Wales, Sydney, Australia. 7. Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain. 8. Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. 9. Institute of Oncology, Rambam Health Care Campus, Haifa, Israel. 10. Rabin Medical Center, Petah Tikva, Israel. 11. Hadassah-Hebrew University Hospital Sharett Institute of Oncology, Jerusalem, Israel; Sharett Institute of Oncology, Jerusalem, Israel. 12. Shaare Zedek Medical Centre, Jerusalem, Israel. 13. Skånes universitetssjuk Lund, Lund, Sweden. 14. AstraZeneca, Macclesfield, UK.
Abstract
OBJECTIVE: The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, was investigated in a subgroup of patients with germline BRCA1/2 mutated (gBRCA1/2m) advanced ovarian cancer who had received ≥3 prior lines of chemotherapy. Primary data from this Phase II study (Study 42, ClinicalTrials.govNCT01078662) have been reported previously. METHODS: Eligible patients were treated with oral olaparib 400mg bid capsule monotherapy until disease progression according to RECIST v1.1. Objective response rate (ORR) and duration of response (DoR) were assessed for patients with measurable disease at baseline. Safety and tolerability were assessed for all patients by adverse event (AE) incidence and changes in laboratory parameters. Platinum resistance status was obtained retrospectively, and responses to olaparib evaluated. RESULTS: In patients with gBRCA1/2m ovarian cancer, 154/193 (80%) had received ≥3 prior lines of chemotherapy, of whom 137/154 (89%) had measurable disease at baseline. ORR was 34% (46/137; 95% confidence interval [CI] 26-42) and median DoR was 7.9 (95% CI 5.6-9.6) months. ORR in platinum-resistant tumors was 30%. Median DoR for platinum-sensitive and platinum-resistant disease was similar: 8.2months (95% CI 5.6-13.5) compared with 8.0months (4.8-14.8), respectively. Six of the 193 (3%) patients had an AE with an outcome of death. None of these AEs at time of occurrence was considered causally related to olaparib. CONCLUSION: Following ≥3 prior lines of chemotherapy, olaparib 400mg bid (capsule form) monotherapy demonstrated notable antitumor activity in patients with gBRCA1/2m advanced ovarian cancer. No new safety signals were identified.
OBJECTIVE: The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, was investigated in a subgroup of patients with germline BRCA1/2 mutated (gBRCA1/2m) advanced ovarian cancer who had received ≥3 prior lines of chemotherapy. Primary data from this Phase II study (Study 42, ClinicalTrials.govNCT01078662) have been reported previously. METHODS: Eligible patients were treated with oral olaparib 400mg bid capsule monotherapy until disease progression according to RECIST v1.1. Objective response rate (ORR) and duration of response (DoR) were assessed for patients with measurable disease at baseline. Safety and tolerability were assessed for all patients by adverse event (AE) incidence and changes in laboratory parameters. Platinum resistance status was obtained retrospectively, and responses to olaparib evaluated. RESULTS: In patients with gBRCA1/2m ovarian cancer, 154/193 (80%) had received ≥3 prior lines of chemotherapy, of whom 137/154 (89%) had measurable disease at baseline. ORR was 34% (46/137; 95% confidence interval [CI] 26-42) and median DoR was 7.9 (95% CI 5.6-9.6) months. ORR in platinum-resistant tumors was 30%. Median DoR for platinum-sensitive and platinum-resistant disease was similar: 8.2months (95% CI 5.6-13.5) compared with 8.0months (4.8-14.8), respectively. Six of the 193 (3%) patients had an AE with an outcome of death. None of these AEs at time of occurrence was considered causally related to olaparib. CONCLUSION: Following ≥3 prior lines of chemotherapy, olaparib 400mg bid (capsule form) monotherapy demonstrated notable antitumor activity in patients with gBRCA1/2m advanced ovarian cancer. No new safety signals were identified.
Authors: Bella Kaufman; Ronnie Shapira-Frommer; Rita K Schmutzler; M William Audeh; Michael Friedlander; Judith Balmaña; Gillian Mitchell; Georgeta Fried; Salomon M Stemmer; Ayala Hubert; Ora Rosengarten; Mariana Steiner; Niklas Loman; Karin Bowen; Anitra Fielding; Susan M Domchek Journal: J Clin Oncol Date: 2014-11-03 Impact factor: 44.544
Authors: Stan B Kaye; Jan Lubinski; Ursula Matulonis; Joo Ern Ang; Charlie Gourley; Beth Y Karlan; Amit Amnon; Katherine M Bell-McGuinn; Lee-May Chen; Michael Friedlander; Tamar Safra; Ignace Vergote; Mark Wickens; Elizabeth S Lowe; James Carmichael; Bella Kaufman Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: Karen A Gelmon; Marc Tischkowitz; Helen Mackay; Kenneth Swenerton; André Robidoux; Katia Tonkin; Hal Hirte; David Huntsman; Mark Clemons; Blake Gilks; Rinat Yerushalmi; Euan Macpherson; James Carmichael; Amit Oza Journal: Lancet Oncol Date: 2011-08-19 Impact factor: 41.316
Authors: Eric Pujade-Lauraine; Uwe Wagner; Elisabeth Aavall-Lundqvist; Val Gebski; Mark Heywood; Paul A Vasey; Birgit Volgger; Ignace Vergote; Sandro Pignata; Annamaria Ferrero; Jalid Sehouli; Alain Lortholary; Gunnar Kristensen; Christian Jackisch; Florence Joly; Chris Brown; Nathalie Le Fur; Andreas du Bois Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: L C Hanker; S Loibl; N Burchardi; J Pfisterer; W Meier; E Pujade-Lauraine; I Ray-Coquard; J Sehouli; P Harter; A du Bois Journal: Ann Oncol Date: 2012-08-21 Impact factor: 32.976
Authors: David S Alberts; P Y Liu; Sharon P Wilczynski; Mary C Clouser; Ana Maria Lopez; David P Michelin; Victor J Lanzotti; Maurie Markman Journal: Gynecol Oncol Date: 2007-10-18 Impact factor: 5.482
Authors: Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono Journal: N Engl J Med Date: 2009-06-24 Impact factor: 91.245
Authors: Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare L Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Brian Dougherty; Maria Orr; Darren Hodgson; J Carl Barrett; Ursula Matulonis Journal: Lancet Oncol Date: 2014-05-31 Impact factor: 41.316
Authors: Narjust Duma; Kelly C Gast; Grace M Choong; Roberto A Leon-Ferre; Ciara C O'Sullivan Journal: Curr Oncol Rep Date: 2018-06-08 Impact factor: 5.075
Authors: Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo Journal: Br J Pharmacol Date: 2017-03-26 Impact factor: 8.739
Authors: Panagiotis A Konstantinopoulos; William T Barry; Michael Birrer; Shannon N Westin; Karen A Cadoo; Geoffrey I Shapiro; Erica L Mayer; Roisin E O'Cearbhaill; Robert L Coleman; Bose Kochupurakkal; Christin Whalen; Jennifer Curtis; Sarah Farooq; Weixiu Luo; Julia Eismann; Mary K Buss; Carol Aghajanian; Gordon B Mills; Sangeetha Palakurthi; Paul Kirschmeier; Joyce Liu; Lewis C Cantley; Scott H Kaufmann; Elizabeth M Swisher; Alan D D'Andrea; Eric Winer; Gerburg M Wulf; Ursula A Matulonis Journal: Lancet Oncol Date: 2019-03-14 Impact factor: 41.316
Authors: Michael J Pishvaian; Edik M Blais; Jonathan R Brody; Emily Lyons; Patricia DeArbeloa; Andrew Hendifar; Sam Mikhail; Vincent Chung; Vaibhav Sahai; Davendra P S Sohal; Sara Bellakbira; Dzung Thach; Lola Rahib; Subha Madhavan; Lynn M Matrisian; Emanuel F Petricoin Journal: Lancet Oncol Date: 2020-03-02 Impact factor: 41.316